Drug therapy for obstructive sleep apnoea in adults

Area of Science:

• Sleep Medicine
• Pharmacology
• Respiratory Medicine

Background:

• Continuous positive airway pressure (CPAP) is the standard treatment for moderate to severe obstructive sleep apnoea (OSA).
• CPAP is not universally tolerated, and its effectiveness in mild OSA is unproven, necessitating alternative treatments.
• Drug therapies are being explored for mild to moderate OSA, particularly for CPAP-intolerant individuals, targeting various mechanisms to reduce airway resistance and improve breathing during sleep.

Purpose of the Study:

• To systematically evaluate the efficacy of pharmacological interventions for the treatment of obstructive sleep apnoea (OSA).
• To assess the impact of various drugs on primary outcomes such as the apnoea-hypopnoea index (AHI) and daytime sleepiness.

Main Methods:

• Conducted a systematic review of randomized, placebo-controlled trials investigating drug therapies for adult OSA patients.
• Searched the Cochrane Airways Group Specialised Register of trials up to July 2012.
• Excluded trials using CPAP, mandibular devices, oxygen therapy, or those focused on associated conditions like obesity or hypertension.

Main Results:

• Thirty trials involving 25 drugs and 516 participants were analyzed, with overall evidence quality rated as low.
• Fluticasone in allergic rhinitis patients and donepezil in non-Alzheimer's patients showed statistically significant reductions in AHI and improved daytime alertness.
• Paroxetine reduced AHI but not daytime symptoms; high-dose ondansetron/fluoxetine combination showed a 40.5% AHI decrease, while mirtazapine led to weight gain and sleepiness.

Conclusions:

• Insufficient evidence currently supports the routine use of drug therapy for obstructive sleep apnoea (OSA).
• While some agents demonstrated short-term AHI reduction (24-45%), further large-scale, longer-duration studies are required for donepezil and fluticasone.
• Personalized drug selection based on individual OSA mechanisms may improve treatment outcomes, warranting further investigation.